Investigation of pharmaceuticals by nuclear magnetic resonance imaging and spectroscopy

• Authors: Zuzanna Bober , David Aebisher , Jacek Tabarkiewicz , Wiesław Guz , Piotr Tutka , Dorota Bartusik-Aebisher
• Languages of publication: EN

Abstracts

EN

Currently, new and easier ways of analyzing pharmaceutical drug forms and drug delivery mechanisms are being sought. Magnetic resonance imaging (MRI) is a non-invasive imaging technique that images drug forms such as tablets, liquids and topicals and drug form behavior in living organisms on both the tissue and cellular scale. The advantages of MRI include noninvasiveness, variable sample capacity and ease of transfer of phantom results to in vitro and in vivo studies. This review concerns the usefulness of clinical MRI that cannot be understated as this technique provides non-invasive and non-destructive insight into the properties of drug delivery systems. The research discussed here concerns the use of magnetic resonance, spectroscopy and chromatography to investigate selected pharmaceuticals and covers work of selecting drugs and antibodies for modification by synthesis for evaluation by MRI. Modifications have been aimed at improving therapeutic efficacy, delivery, and MRI. Modification conditions such as (pH, concentration, temperature, and the influence of other components present in the solutions) will be discussed to understand drug delivery system improvements and the reliability and repeatability of the results obtained. We hope to explore and expand the scope of pharmaceutical imaging with MRI for application in clinical medicine.

Keywords

EN

drug delivery systems; drug forms; magnetic resonance imaging pharmaceuticals

• Publisher: Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
• Journal: European Journal of Clinical and Experimental Medicine
• Year: 2017
• Issue: 2
• Pages: 110-119

Contributors

author

Zuzanna Bober

• Center for Innovative Research in Medical and Natural Sciences, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland

author

David Aebisher

• Department of Human Immunology, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland

author

Jacek Tabarkiewicz

• Center for Innovative Research in Medical and Natural Sciences, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland
• Department of Human Immunology, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland

author

Wiesław Guz

• Center for Innovative Research in Medical and Natural Sciences, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland
• Department of Electroradiology, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland

author

Piotr Tutka

• Center for Innovative Research in Medical and Natural Sciences, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland
• Department of Experimental and Clinical Pharmacology, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland

author

Dorota Bartusik-Aebisher

• Department of Experimental and Clinical Pharmacology, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland

Identifiers

DOI

10.15584/ejcem.2017.2.3